Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03134118 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

Study acronym: NIVOTHYM
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Dec 2023 to Sep 5, 2023
    • Study completion date: Jul 2024 to Dec 2027
    v15
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 20 of 20 sites
    v14
  3. Primary completion date: Jul 2021 to Dec 2023
    • Study sites: 17 to 20
    • Study completion date: Jul 2021 to Jul 2024
    v13
  4. Re-verified, no change to tracked fieldsv12
  5. Study sites: 15 to 17v11
Show 9 earlier versionsHide 9 earlier versions
  1. Study sites: 13 to 15v10
  2. Study sites: 6 to 13v9
  3. Re-verified, no change to tracked fieldsv8
  4. Study sites: 3 to 6
    • Start date changed from estimate of Apr 2018 to Apr 11, 2018
    v7
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 2 to 3
    v6
  6. Eligibility criteria shortened, about 1 wordv5
  7. Start date: Jan 2018 to Apr 2018v4
  8. Re-verified, no change to tracked fieldsv3
  9. Study title shortened, about 4 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.
Trial Details
NCT Number NCT03134118
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: ETOP IBCSG Partners Foundation
Conditions
(from sponsor)		 Thymoma Type B3, Thymic Carcinoma
Related terms Thymoma
Enrollment 55 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov